Yes just saw the 8k, very nice, this is huge folks!!
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act
January 3, 2011
Date of Report
(Date of earliest event reported)
GeNOsys, INC.
(Exact name of registrant as specified in its charter)
Utah
000-49817
87-0671592
(State or Other Jurisdiction of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
86 N. University Ave., Suite 400
Provo, Utah 84601
(Address of Principal Executive Offices)
(801) 623-4751
(Registrant's Telephone Number)
N/A
(Former Name or Former Address if changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see general instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14-a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 3, 2011, the Board of Directors of GeNOsys, Inc. (the “Company”) appointed Gordon D. Barker and Keith L. Merrell as directors of the Company. Both will serve until the 2011 Annual Meeting of Shareholders and until their successor is duly elected and qualified. Mr. Merrell has served as our Chief Financial Officer and will continue in that position. Neither Mr. Barker or Mr. Merrell have been appointed to any committees of the Board of Directors.
There is no arrangement or understanding between either Mr. Barker or Mr. Merrell and any other person pursuant to which either was selected to serve as a director of the Company; neither has a family relationship with any director, executive officer or person nominated as such of the Company.
Since the beginning of the Company’s last fiscal year, there was no transaction or series of similar transactions, nor is there any currently proposed transaction or series of similar transactions, to which the Company or any of its subsidiaries was or is to be a party, in which the amount involved exceeds $120,000 and in which Mr. Barker or Mr. Merrell, or members of their immediate family, had or will have a direct or indirect material interest.
On January 11, 2011, the Company issued a press release announcing the appointment of Mr. Barker and Mr. Merrell to the Company’s Board of Directors, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by this reference
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1
Press Release dated January 11, 2011
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
GeNOsys, INC.
Date: 1/11/2011
By/s/John W. R. Miller
President and director
GeNOsys Appoints Two Directors
PROVO, Utah.—January 11, 2011 GeNOsys, Inc. (OTCBB: GNYS) today announced the appointment of two additional directors. Mr. Gordon D. Barker and Mr. Keith L. Merrell have accepted board positions.
Mr. Barker served as the Chief Executive Officer of Thrifty Payless Drug Stores, Inc., a $5.1 billion company, and was instrumental in negotiating its merger with Rite-Aid Drugs. Mr. Barker currently serves on a number of Board of Directors for both public and private companies, including Vice Chairman and Lead Outside Independent Director of United Natural Foods, Inc., NuMedics, Inc., and American Consulting Technology & Research. Mr. Barker has also served as Chairman of the Juvenile Diabetes Research Foundation International.
Mr. Merrell has made valuable contributions as the Chief Financial Officer of GeNOsys. Prior to joining GeNOsys, he was the Chief Financial Officer of Specialized Health Products, Inc., a public company which developed and manufactured medical devices which required FDA approval before they could be introduced into the marketplace.
“We are very fortunate to have a person with the experience of Mr. Barker join our board. His vision and experience will be invaluable as we develop our product strategies,” stated Mr. John W.R. Miller, Chairman of the Board. “Mr. Merrell is also a valued addition to our board, bringing his financial, manufacturing and FDA regulatory experience.”
About GeNOsys:
GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas will be one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company’s Website at: www.genosysusa.com.
This press release may contain forward-looking statements including the Company’s beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company’s filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.
--------------------------------------------------------------------------------
Contact:
GeNOsys, Inc.
Keith Merrell, 801-623-4751
kmerrell@genosysusa.com
Source: GeNOsys, Inc.
News 
Market Data 
Discover 
AI
